Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ES-481 in adults with drug resistant epilepsy
ACTRN12621000033842Phase 2Recruiting
- Sponsor
- ES Therapeutics LLC
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of es-481 in epilepsy (2 arms), sponsored by ES Therapeutics LLC. Primary endpoint: Change in seizure frequency and seizure activity. Started Jan 2021; status: recruiting.
02
Drugs
es-481
03
Conditions
epilepsy
Beyond the preview
Go deeper on ACTRN12621000033842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000033842.